Free Trial

Flossbach Von Storch SE Has $154.02 Million Position in Ralliant Corporation $RAL

Ralliant logo with Manufacturing background
Image from MarketBeat Media, LLC.

Key Points

  • Flossbach Von Storch SE cut its position in Ralliant by 27.1%, selling 1,127,445 shares and retaining 3,025,421 shares worth about $154.02 million (2.68% ownership).
  • Insider buying increased: SVP Amir Kazmi and Director Kate Mitchell bought shares, and insiders acquired 8,145 shares valued at roughly $332,233 over the last quarter.
  • Several analysts trimmed price targets (e.g., Truist, RBC, Citi, Barclays) but the consensus remains a Moderate Buy with a $50.50 target; Ralliant also beat Q results (EPS $0.69 vs. $0.67) and set FY2026 guidance of 2.220–2.420 EPS.
  • Five stocks to consider instead of Ralliant.

Flossbach Von Storch SE lessened its holdings in shares of Ralliant Corporation (NYSE:RAL - Free Report) by 27.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,025,421 shares of the company's stock after selling 1,127,445 shares during the period. Flossbach Von Storch SE owned 2.68% of Ralliant worth $154,024,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. V Square Quantitative Management LLC acquired a new position in Ralliant during the 4th quarter worth about $26,000. Westfuller Advisors LLC acquired a new stake in Ralliant in the 3rd quarter valued at about $26,000. Palisade Asset Management LLC bought a new position in shares of Ralliant in the third quarter worth about $26,000. UMB Bank n.a. bought a new position in shares of Ralliant in the third quarter worth about $29,000. Finally, BOKF NA acquired a new position in shares of Ralliant during the third quarter worth approximately $29,000.

Insider Buying and Selling at Ralliant

In related news, SVP Amir A. Kazmi bought 2,545 shares of Ralliant stock in a transaction on Friday, February 6th. The shares were purchased at an average price of $39.27 per share, for a total transaction of $99,942.15. Following the completion of the acquisition, the senior vice president owned 39,699 shares in the company, valued at approximately $1,558,979.73. This represents a 6.85% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kate Mitchell bought 2,350 shares of Ralliant stock in a transaction on Tuesday, February 10th. The shares were bought at an average price of $42.48 per share, for a total transaction of $99,828.00. Following the acquisition, the director owned 8,411 shares of the company's stock, valued at approximately $357,299.28. The trade was a 38.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 8,145 shares of company stock valued at $332,233 over the last quarter.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Truist Financial decreased their price target on shares of Ralliant from $62.00 to $49.00 and set a "buy" rating on the stock in a research note on Friday, February 6th. Royal Bank Of Canada reduced their price objective on Ralliant from $52.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 6th. Citigroup decreased their price objective on Ralliant from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday, February 6th. Barclays lowered their target price on Ralliant from $60.00 to $52.00 and set an "overweight" rating for the company in a research note on Monday, February 9th. Finally, Zacks Research raised Ralliant from a "strong sell" rating to a "hold" rating in a research note on Monday, April 13th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $50.50.

View Our Latest Report on RAL

Ralliant Trading Down 0.5%

RAL opened at $44.42 on Tuesday. The firm has a 50 day simple moving average of $44.08 and a 200 day simple moving average of $46.87. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $57.02. The company has a market cap of $4.97 billion and a price-to-earnings ratio of 22.66. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 0.58.

Ralliant (NYSE:RAL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.02. The business had revenue of $554.60 million during the quarter, compared to the consensus estimate of $543.04 million. The firm's revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS. On average, sell-side analysts anticipate that Ralliant Corporation will post 2.37 earnings per share for the current year.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 23rd. Stockholders of record on Monday, March 9th were given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Monday, March 9th. Ralliant's dividend payout ratio (DPR) is currently 10.20%.

About Ralliant

(Free Report)

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Featured Articles

Institutional Ownership by Quarter for Ralliant (NYSE:RAL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ralliant Right Now?

Before you consider Ralliant, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ralliant wasn't on the list.

While Ralliant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines